Last reviewed · How we verify

NCT07362433: BLAAAST

Trial of an AI-enabled Digital Stethoscope to Improve Antibiotic Stewardship

Not yet recruiting Phase 4 Last updated 23 January 2026
What this trial tests

Phase 4 trial testing Automated digital stethoscope in Respiratory Infections in Children in 2,500 participants. Not yet recruiting.

Timeline
1 May 2026
Primary endpoint
30 June 2029
30 June 2029

Quick facts

Lead sponsorJohns Hopkins University
PhasePhase 4
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposediagnostic
Enrollment2,500
Start date1 May 2026
Primary completion30 June 2029
Estimated completion30 June 2029
Sites1 location across Bangladesh

Drugs / interventions tested

Conditions studied

Sponsor

Johns Hopkins University

Who can join

Adults 2 Months to 59 Months, any sex, with Respiratory Infections in Children. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Antibiotics are a mainstay of the treatment of lower respiratory infections in young children even though most episodes are caused by self-limiting viruses. Innovative child friendly tools that improve the diagnosis of respiratory illnesses, safely reduce the unnecessary use of antibiotics, and are suitable for implementation in resource-constrained settings are urgently required to safely improve antibiotic stewardship and stem the rising rates of antibiotic resistance globally. In the Bangladesh Lung Auscultation Artificial Intelligence for Antibiotic Stewardship Trial (BLAAAST) the investigators aim to determine whether treatment failure frequency among children in rural Bangladesh managed by clinical guidelines enhanced by a commercially available, artificial intelligence (AI)-enabled digital stethoscope is non-inferior to guidelines alone. The investigators hypothesize treatment failure frequency among 'enhanced IMCI' participants will be no worse than standard care by a +/-2% margin, safely reducing antibiotic use by 50-60%. The investigators will also evaluate if a diagnostic strategy enhanced by an AI-enabled digital stethoscope is a sustainable alternative to standard care for children in rural Bangladesh. The investigators hypothesize that care augmented by an AI-enabled digital stethoscope will have additional benefits via reduced antibiotic use that will outweigh digital auscultation costs resulting in cost-effectiveness compared to current practice. BLAAAST affords a unique opportunity to evaluate the efficacy of clinical guidelines enhanced by an AI-enabled digital stethoscope on child pneumonia outcomes in Bangladesh, if digital auscultation may be instrumental in the wider antibiotic stewardship strategy, and whether a digital stethoscope diagnostic tool is cost-effective in the care of children with respiratory illnesses.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Johns Hopkins University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07362433.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing